Financial targets and future outlook

Last modified: 23.3.2020

Financial targets, dividend policy and future outlook

Growth

Optomed’s medium-term, from 2020 onwards, target is to deliver a double digit annual organic revenue growth.

In the long-term Optomed’s target is to deliver an average annual organic revenue growth above 20 percent.

Adjusted EBITDA-margin

Optomed’s target in the medium-term is to prioritise investments in the organisation to support growth and achieve an adjusted EBITDA margin above 30% in the long-term.

Dividend policy

Optomed is in expansion phase and will therefore prioritise growth over dividends in coming years.

Future outlook

We continue to progress our expansion towards the US and grow our international distributor network. Additionally, we are currently investing in the development of our first fully integrated AI camera with expected commercial launch during 2020.

Optomed expects its revenue to decline during 2020.

The COVID-19 pandemic has a negative effect on Optomed’s growth and business in 2020.

(announced 19 March 2020)

 

Previous outlook of 28 February 2020:

We continue to progress our expansion towards the US and grow our international distributor network. Additionally, we are currently investing in the development of our first fully integrated AI camera with expected commercial launch during 2020.

Optomed expects its revenue to grow during 2020 and that the growth will focus on the second half of the year.

The COVID-19 Coronavirus outbreak may have a negative impact on the company’s growth affecting both the business in China and the overall business due to the company’s Chinese component suppliers. Further, in case the virus becomes pandemic the company’s global sales could be negatively affected.